Takeda Pharmaceutical (TAK) Competitors $13.28 -0.33 (-2.42%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends TAK vs. SNY, GSK, BNTX, TEVA, BGNE, VTRS, SMMT, MRNA, GMAB, and RDYShould you be buying Takeda Pharmaceutical stock or one of its competitors? The main competitors of Takeda Pharmaceutical include Sanofi (SNY), GSK (GSK), BioNTech (BNTX), Teva Pharmaceutical Industries (TEVA), BeiGene (BGNE), Viatris (VTRS), Summit Therapeutics (SMMT), Moderna (MRNA), Genmab A/S (GMAB), and Dr. Reddy's Laboratories (RDY). These companies are all part of the "pharmaceutical products" industry. Takeda Pharmaceutical vs. Sanofi GSK BioNTech Teva Pharmaceutical Industries BeiGene Viatris Summit Therapeutics Moderna Genmab A/S Dr. Reddy's Laboratories Takeda Pharmaceutical (NYSE:TAK) and Sanofi (NASDAQ:SNY) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, earnings, analyst recommendations, valuation, dividends, community ranking, media sentiment and institutional ownership. Is TAK or SNY a better dividend stock? Takeda Pharmaceutical pays an annual dividend of $0.48 per share and has a dividend yield of 3.6%. Sanofi pays an annual dividend of $1.47 per share and has a dividend yield of 3.1%. Takeda Pharmaceutical pays out 82.8% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Sanofi pays out 75.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Which has more volatility and risk, TAK or SNY? Takeda Pharmaceutical has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. Comparatively, Sanofi has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Do analysts rate TAK or SNY? Sanofi has a consensus price target of $57.50, indicating a potential upside of 20.34%. Given Sanofi's stronger consensus rating and higher possible upside, analysts clearly believe Sanofi is more favorable than Takeda Pharmaceutical.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Takeda Pharmaceutical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Sanofi 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 2.75 Do insiders and institutionals have more ownership in TAK or SNY? 9.2% of Takeda Pharmaceutical shares are owned by institutional investors. Comparatively, 10.0% of Sanofi shares are owned by institutional investors. 0.0% of Takeda Pharmaceutical shares are owned by company insiders. Comparatively, 1.0% of Sanofi shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Is TAK or SNY more profitable? Sanofi has a net margin of 9.96% compared to Takeda Pharmaceutical's net margin of 6.49%. Sanofi's return on equity of 27.45% beat Takeda Pharmaceutical's return on equity.Company Net Margins Return on Equity Return on Assets Takeda Pharmaceutical6.49% 10.00% 4.78% Sanofi 9.96%27.45%15.79% Does the MarketBeat Community believe in TAK or SNY? Takeda Pharmaceutical received 51 more outperform votes than Sanofi when rated by MarketBeat users. However, 62.82% of users gave Sanofi an outperform vote while only 56.82% of users gave Takeda Pharmaceutical an outperform vote. CompanyUnderperformOutperformTakeda PharmaceuticalOutperform Votes10056.82% Underperform Votes7643.18% SanofiOutperform Votes4962.82% Underperform Votes2937.18% Does the media prefer TAK or SNY? In the previous week, Sanofi had 15 more articles in the media than Takeda Pharmaceutical. MarketBeat recorded 20 mentions for Sanofi and 5 mentions for Takeda Pharmaceutical. Sanofi's average media sentiment score of 0.89 beat Takeda Pharmaceutical's score of 0.50 indicating that Sanofi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Takeda Pharmaceutical 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sanofi 9 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings & valuation, TAK or SNY? Sanofi has higher revenue and earnings than Takeda Pharmaceutical. Takeda Pharmaceutical is trading at a lower price-to-earnings ratio than Sanofi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTakeda Pharmaceutical$28.20B1.50$994.06M$0.5822.91Sanofi$48.86B2.48$5.84B$1.9624.38 SummarySanofi beats Takeda Pharmaceutical on 19 of the 21 factors compared between the two stocks. Ad DTIWhen it comes to NVDA… “acceleration cycles” are the keyExpert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again.Use this link to see Nvidia Unchained right away! Get Takeda Pharmaceutical News Delivered to You Automatically Sign up to receive the latest news and ratings for TAK and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TAK vs. The Competition Export to ExcelMetricTakeda PharmaceuticalPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$42.29B$6.40B$5.01B$19.90BDividend Yield3.50%8.11%5.18%3.54%P/E Ratio22.9110.06132.0342.58Price / Sales1.50318.831,202.2518.15Price / Cash4.2022.1633.2717.85Price / Book0.845.454.685.66Net Income$994.06M$152.96M$118.21M$984.91M7 Day Performance-2.03%-4.28%-2.36%-0.16%1 Month Performance-7.26%-8.65%-3.97%0.18%1 Year Performance-5.21%28.57%29.71%23.72% Takeda Pharmaceutical Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TAKTakeda Pharmaceutical3.4202 of 5 stars$13.29-2.4%N/A-5.2%$43.34B$28.20B22.9149,281High Trading VolumeSNYSanofi2.8072 of 5 stars$47.78-0.5%$57.50+20.3%+2.8%$121.82B$46.61B24.3886,088Analyst RevisionGSKGSK4.4031 of 5 stars$33.36-0.3%$43.25+29.6%-5.0%$69.14B$37.71B21.6670,200Options VolumeBNTXBioNTech3.4698 of 5 stars$102.14-4.0%$138.79+35.9%+3.3%$24.49B$3.04B-48.646,133Analyst ForecastAnalyst RevisionTEVATeva Pharmaceutical Industries2.6924 of 5 stars$17.03+1.2%$19.67+15.5%+80.0%$19.04B$15.85B0.0037,851BGNEBeiGene3.174 of 5 stars$194.26+3.5%$247.07+27.2%+3.4%$18.92B$2.46B-23.5810,600Analyst DowngradeGap UpVTRSViatris1.3448 of 5 stars$13.13+0.6%$13.33+1.5%+38.6%$15.67B$15.05B-17.7438,000SMMTSummit Therapeutics1.863 of 5 stars$18.62-6.9%$34.75+86.6%+835.7%$14.75B$700,000.000.00105Analyst ForecastMRNAModerna4.6267 of 5 stars$36.94-0.9%$84.00+127.4%-53.2%$14.22B$6.85B-6.355,600Analyst UpgradeAnalyst RevisionGMABGenmab A/S4.3073 of 5 stars$20.45-0.2%$45.20+121.0%-37.0%$13.53B$19.84B19.852,204RDYDr. Reddy's Laboratories1.3247 of 5 stars$14.30-0.3%$17.00+18.9%+5.9%$11.94B$299.87B22.7027,048 Related Companies and Tools Related Companies SNY Competitors GSK Competitors BNTX Competitors TEVA Competitors BGNE Competitors VTRS Competitors SMMT Competitors MRNA Competitors GMAB Competitors RDY Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:TAK) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Takeda Pharmaceutical Company Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Takeda Pharmaceutical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TAK Stock Alerts